224 related articles for article (PubMed ID: 30947579)
1. Clinicopathological features of clinical methotrexate-related lymphoproliferative disorders.
Tokuhira M; Saito S; Suzuki K; Higashi M; Momose S; Shimizu T; Mori T; Kimura Y; Amano K; Okamoto S; Takeuchi T; Tamaru JI; Kizaki M
Leuk Lymphoma; 2019 Oct; 60(10):2508-2515. PubMed ID: 30947579
[TBL] [Abstract][Full Text] [Related]
2. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication.
Hoshida Y; Xu JX; Fujita S; Nakamichi I; Ikeda J; Tomita Y; Nakatsuka S; Tamaru J; Iizuka A; Takeuchi T; Aozasa K
J Rheumatol; 2007 Feb; 34(2):322-31. PubMed ID: 17117491
[TBL] [Abstract][Full Text] [Related]
3. The clinical impact of absolute lymphocyte count in peripheral blood among patients with methotrexate - associated lymphoproliferative disorders.
Tokuhira M; Tanaka Y; Takahashi Y; Kimura Y; Tomikawa T; Anan T; Watanabe J; Sagawa M; Higashi M; Momose S; Amano K; Tabayashi T; Nakaseko R; Tamaru JI; Kizaki M
J Clin Exp Hematop; 2020 Jun; 60(2):41-50. PubMed ID: 32404570
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs.
Harada T; Iwasaki H; Muta T; Urata S; Sakamoto A; Kohno K; Takase K; Miyamura T; Sawabe T; Asaoku H; Oryoji K; Fujisaki T; Mori Y; Yoshimoto G; Ayano M; Mitoma H; Miyamoto T; Niiro H; Yamamoto H; Oshiro Y; Miyoshi H; Ohshima K; Takeshita M; Akashi K; Kato K
Br J Haematol; 2021 Jul; 194(1):101-110. PubMed ID: 33822354
[TBL] [Abstract][Full Text] [Related]
5. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases.
Salloum E; Cooper DL; Howe G; Lacy J; Tallini G; Crouch J; Schultz M; Murren J
J Clin Oncol; 1996 Jun; 14(6):1943-9. PubMed ID: 8656264
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate-associated orbital lymphoproliferative disorder in a patient with rheumatoid arthritis: a case report.
Kobayashi Y; Kimura K; Fujitsu Y; Shinkawa K; Muta H; Sonoda KH
Jpn J Ophthalmol; 2016 May; 60(3):212-8. PubMed ID: 27018050
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate-related lymphoproliferative disorder of the stomach in a patient with rheumatoid arthritis: a case of disease regression after methotrexate cessation.
Ikeda K; Nakamura T; Kinoshita T; Fujiwara M; Uose S; Someda H; Miyoshi T; Io K; Nagai K
Clin J Gastroenterol; 2016 Feb; 9(1):17-21. PubMed ID: 26733461
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate-associated Lymphoproliferative Disorder of the Stomach Presumed to Be Mucosa-associated Lymphoid Tissue Lymphoma.
Ishigaki S; Masaoka T; Kameyama H; Kawaida M; Kameyama K; Mori T; Kanai T
Intern Med; 2018; 57(22):3249-3254. PubMed ID: 30429434
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate-associated lymphoproliferative disorders: management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal.
Inui Y; Matsuoka H; Yakushijin K; Okamura A; Shimada T; Yano S; Takeuchi M; Ito M; Murayama T; Yamamoto K; Itoh T; Aiba K; Minami H
Leuk Lymphoma; 2015; 56(11):3045-51. PubMed ID: 25721751
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 expression is associated with the spontaneous regression of patients with methotrexate-associated lymphoproliferative disorders.
Gion Y; Doi M; Nishimura Y; Ikeda T; Filiz Nishimura M; Sakamoto M; Egusa Y; Nishikori A; Fujita A; Iwaki N; Nakamura N; Yoshino T; Sato Y
Cancer Med; 2022 Jan; 11(2):417-432. PubMed ID: 34842351
[TBL] [Abstract][Full Text] [Related]
11. Mature T/NK-cell lymphoproliferative disease and Epstein-Barr virus infection are more frequent in patients with rheumatoid arthritis treated with methotrexate.
Kondo S; Tanimoto K; Yamada K; Yoshimoto G; Suematsu E; Fujisaki T; Oshiro Y; Tamura K; Takeshita M; Okamura S
Virchows Arch; 2013 Apr; 462(4):399-407. PubMed ID: 23494713
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents.
Katsuyama T; Sada KE; Yan M; Zeggar S; Hiramatsu S; Miyawaki Y; Ohashi K; Morishita M; Watanabe H; Katsuyama E; Takano-Narazaki M; Toyota-Tatebe N; Sunahori-Watanabe K; Kawabata T; Miyake K; Kiguchi T; Wada J
Mod Rheumatol; 2017 Sep; 27(5):773-777. PubMed ID: 27846761
[TBL] [Abstract][Full Text] [Related]
13. [Primary central nervous system methotrexate associated lymphoproliferative disorders in a patient with rheumatoid arthritis].
Uchida Y; Hokkoku K; Hatanaka Y; Kikuchi Y; Tashiro H; Sonoo M
Rinsho Shinkeigaku; 2018 Aug; 58(8):485-491. PubMed ID: 30068810
[TBL] [Abstract][Full Text] [Related]
14. Methotrexate-associated Lymphoproliferative Disorders in Patients With Rheumatoid Arthritis: Clinicopathologic Features and Prognostic Factors.
Kurita D; Miyoshi H; Ichikawa A; Kato K; Imaizumi Y; Seki R; Sato K; Sasaki Y; Kawamoto K; Shimono J; Yamada K; Muto R; Kizaki M; Nagafuji K; Tamaru JI; Tokuhira M; Ohshima K
Am J Surg Pathol; 2019 Jul; 43(7):869-884. PubMed ID: 31116708
[TBL] [Abstract][Full Text] [Related]
15. Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate.
Saito S; Kaneko Y; Yamaoka K; Tokuhira M; Takeuchi T
Rheumatology (Oxford); 2017 Jun; 56(6):940-946. PubMed ID: 28165538
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical Assessment of the Diagnostic Utility of PD-L1 (Clone SP142) for Methotrexate-Associated Lymphoproliferative Disorders With an Emphasis of Neoplastic PD-L1 (Clone SP142)-Positive Classic Hodgkin Lymphoma Type.
Kohno K; Suzuki Y; Elsayed AA; Sakakibara A; Takahara T; Satou A; Kato S; Nakamura S; Asano N
Am J Clin Pathol; 2020 Apr; 153(5):571-582. PubMed ID: 31977037
[TBL] [Abstract][Full Text] [Related]
17. Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders.
Nakano K; Saito K; Nawata A; Hanami K; Kubo S; Miyagawa I; Fujino Y; Nakayamada S; Tanaka Y
Mod Rheumatol; 2021 Jan; 31(1):94-100. PubMed ID: 32159414
[TBL] [Abstract][Full Text] [Related]
18. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression.
Ichikawa A; Arakawa F; Kiyasu J; Sato K; Miyoshi H; Niino D; Kimura Y; Takeuchi M; Yoshida M; Ishibashi Y; Nakashima S; Sugita Y; Miura O; Ohshima K
Eur J Haematol; 2013 Jul; 91(1):20-8. PubMed ID: 23560463
[TBL] [Abstract][Full Text] [Related]
19. A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders.
Yamakawa N; Fujimoto M; Kawabata D; Terao C; Nishikori M; Nakashima R; Imura Y; Yukawa N; Yoshifuji H; Ohmura K; Fujii T; Kitano T; Kondo T; Yurugi K; Miura Y; Maekawa T; Saji H; Takaori-Kondo A; Matsuda F; Haga H; Mimori T
J Rheumatol; 2014 Feb; 41(2):293-9. PubMed ID: 24334644
[TBL] [Abstract][Full Text] [Related]
20. A case of multiple hepatic lesions associated with methotrexate-associated lymphoproliferative disorder.
Matsumoto R; Numata K; Doba N; Hara K; Chuma M; Fukuda H; Nozaki A; Tanaka K; Ishii Y; Maeda S
J Med Ultrason (2001); 2016 Oct; 43(4):545-51. PubMed ID: 27577564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
